Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma

Differentiation of Tumor Progression from Pseudoprogression in Patients with Posttreatment Glioblastoma Using Multiparametric Histogram Analysis

(2014) J. Cha et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme

(2014) Paul Sanghera et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

ADC texture-An imaging biomarker for high-grade glioma?

(2014) Patrik Brynolfsson et al.   MEDICAL PHYSICS

Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence

(2014) A. Radbruch et al.   NEURO-ONCOLOGY

Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question

(2014) M. Nasseri et al.   NEURO-ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy

(2013) Olivier L. Chinot et al.   Current Neurology and Neuroscience Reports

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

(2012) Evanthia Galanis et al.   LANCET ONCOLOGY

Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status

(2011) D.-S. Kong et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

(2011) L.C. Hygino da Cruz et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma

(2011) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab

(2011) W. B. Pope et al.   NEUROLOGY

Bevacizumab does not increase the risk of remote relapse in malignant glioma

(2010) Antje Wick et al.   ANNALS OF NEUROLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

(2009) Jennifer L. Clarke et al.   Current Neurology and Neuroscience Reports

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF NEURO-ONCOLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

(2008) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY